JP2011000128A5 - - Google Patents

Download PDF

Info

Publication number
JP2011000128A5
JP2011000128A5 JP2010208097A JP2010208097A JP2011000128A5 JP 2011000128 A5 JP2011000128 A5 JP 2011000128A5 JP 2010208097 A JP2010208097 A JP 2010208097A JP 2010208097 A JP2010208097 A JP 2010208097A JP 2011000128 A5 JP2011000128 A5 JP 2011000128A5
Authority
JP
Japan
Prior art keywords
pyy
pancreatic
composition
peptide
islet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010208097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011000128A (ja
JP5766419B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011000128A publication Critical patent/JP2011000128A/ja
Publication of JP2011000128A5 publication Critical patent/JP2011000128A5/ja
Application granted granted Critical
Publication of JP5766419B2 publication Critical patent/JP5766419B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010208097A 1999-02-10 2010-09-16 グルコース代謝障害を治療する方法および試薬 Expired - Fee Related JP5766419B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11957799P 1999-02-10 1999-02-10
US60/119,577 1999-02-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000598171A Division JP2003518914A (ja) 1999-02-10 2000-02-10 グルコース代謝障害を治療する方法および試薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013128670A Division JP2013188229A (ja) 1999-02-10 2013-06-19 グルコース代謝障害を治療する方法および試薬

Publications (3)

Publication Number Publication Date
JP2011000128A JP2011000128A (ja) 2011-01-06
JP2011000128A5 true JP2011000128A5 (enExample) 2011-12-22
JP5766419B2 JP5766419B2 (ja) 2015-08-19

Family

ID=22385149

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000598171A Pending JP2003518914A (ja) 1999-02-10 2000-02-10 グルコース代謝障害を治療する方法および試薬
JP2010208097A Expired - Fee Related JP5766419B2 (ja) 1999-02-10 2010-09-16 グルコース代謝障害を治療する方法および試薬
JP2013128670A Pending JP2013188229A (ja) 1999-02-10 2013-06-19 グルコース代謝障害を治療する方法および試薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000598171A Pending JP2003518914A (ja) 1999-02-10 2000-02-10 グルコース代謝障害を治療する方法および試薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013128670A Pending JP2013188229A (ja) 1999-02-10 2013-06-19 グルコース代謝障害を治療する方法および試薬

Country Status (12)

Country Link
US (1) US7396809B1 (enExample)
EP (1) EP1189629B1 (enExample)
JP (3) JP2003518914A (enExample)
AT (1) ATE482717T1 (enExample)
AU (2) AU779745C (enExample)
CA (1) CA2360324C (enExample)
DE (1) DE60045030D1 (enExample)
DK (1) DK1189629T3 (enExample)
ES (1) ES2353728T3 (enExample)
HK (1) HK1045267A1 (enExample)
IL (2) IL144703A (enExample)
WO (1) WO2000047219A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DE60045030D1 (de) * 1999-02-10 2010-11-11 Curis Inc Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
RU2275207C2 (ru) * 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
AU2007200224B2 (en) * 2000-12-14 2009-10-01 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
JP4975221B2 (ja) * 2001-06-01 2012-07-11 協和メデックス株式会社 α−アミラーゼ活性測定用試薬と測定方法
EP2022505B1 (en) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CN100350968C (zh) * 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
JP4733922B2 (ja) * 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
CN1668759A (zh) * 2002-05-17 2005-09-14 协和发酵工业株式会社 具有抗糖尿病作用的物质的探索方法
EP1581245A2 (en) 2002-12-17 2005-10-05 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005016911A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
PA8660701A1 (es) * 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
AU2006235216C1 (en) * 2005-04-13 2012-01-19 Garvan Institute Of Medical Research Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
US8236933B2 (en) * 2005-04-13 2012-08-07 Garvan Institute Of Medical Research Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
WO2012054523A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2012150707A1 (ja) 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
CN103981147B (zh) * 2013-02-08 2017-11-10 中国科学院上海生命科学研究院 一种新的制备肝实质细胞的方法
US9878071B2 (en) 2013-10-16 2018-01-30 Purdue Research Foundation Collagen compositions and methods of use
EP4548939A3 (en) 2014-08-27 2025-08-06 Purdue Research Foundation Collagen-based therapeutic delivery systems
WO2016172365A1 (en) 2015-04-21 2016-10-27 Purdue Research Foundation Office Of Technology Commercialization Cell-collagen-silica composites and methods of making and using the same
EP3316872A4 (en) * 2015-07-02 2018-12-26 Rani Therapeutics, LLC Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
CA3052266A1 (en) 2017-01-31 2018-08-09 Geniphys, Llc Methods and compositions for matrix preparation
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2018200750A1 (en) 2017-04-25 2018-11-01 Purdue Research Foundation 3-dimensional (3d) tissue-engineered muscle for tissue restoration
US12458669B2 (en) 2017-07-25 2025-11-04 Purdue Research Foundation Collagen encapsulation of insulin-producing cells
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
WO2021154845A1 (en) 2020-01-27 2021-08-05 Geniphys, Llc Biologic filler for restoring and regenerating tissue

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891357A (en) 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4839343A (en) 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
WO1989001967A1 (en) 1987-09-03 1989-03-09 Brown University Research Foundation Blood purification with cultured renal cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FI916066A7 (fi) 1989-06-21 1991-12-20 Brown Univ Research Foundation Neurologinen hoitojärjestelmä
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
HUT73494A (en) 1993-03-29 1996-08-28 Univ Cincinnati Analogs of peptide yy and uses thereof
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
WO1995011689A1 (en) 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) * 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US20020094346A1 (en) 1995-05-17 2002-07-18 M. D. Henry C. Lin Method and compositions for improving digestion and absorption in the small intestine
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
WO1998020885A1 (en) * 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
CA2251368A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
EP0992239B1 (en) 1997-04-23 2003-03-12 Banyu Pharmaceutical Co., Ltd. Neuropeptide y receptor antagonist
WO1999015516A1 (en) 1997-09-25 1999-04-01 Banyu Pharmaceutical Co., Ltd. Novel neuropeptide y receptor antagonists
US6013622A (en) 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
DE60045030D1 (de) * 1999-02-10 2010-11-11 Curis Inc Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
MXPA01011321A (es) 1999-05-05 2003-08-01 Johnson & Johnson Neuropeptidos y ligandos de receptores 3a, 4, 5, 9b-tetrahidro-1h-benz(e)indol-2-il amino derivados utiles en el tratamiento de obesidad y otros trastornos.
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进

Similar Documents

Publication Publication Date Title
JP2011000128A5 (enExample)
JP5189723B2 (ja) 骨関連疾患及び栄養関連疾患の治療、予防、診断及び予後のためにｇｌｐを使用する方法
CN102363633B (zh) 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
AU779745B2 (en) Methods and reagents for treating glucose metabolic disorders
JP2004524268A5 (enExample)
EA013121B1 (ru) Амилин и агонисты амилина для лечения психиатрических заболеваний и расстройств
EP2937088B1 (en) Composition having tissue repairing activity and utilization thereof
US20040052862A1 (en) Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
Sharma et al. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
TW200843794A (en) Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
Huang et al. p38-MAPK pathway is activated in retinopathy of microvascular disease of STZ-induced diabetic rat model.
Padrutt et al. Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats
CN101466398A (zh) 稳定的胰岛素样生长因子多肽
KR101661332B1 (ko) 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
CN115414483B (zh) Adrb1活性抑制剂在作为或制备用于治疗银屑病的制剂中的应用
US20130244932A1 (en) E-prostanoid receptor, ptger3, as a novel anti-diabetic therapeutic target
KR20070116587A (ko) 유착 관절낭염을 치료하는 방법
Zhang et al. Cytokine storms caused by novel coronavirus 2019 and treatment for cardiac injury.
MX2008012666A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.
CN104619326A (zh) 骨系统疾病治疗药及其用途
US20230210942A1 (en) Methods and compositions for modulating endothelial cell dysfunction
US20210236594A1 (en) Methods for improving frailty and aging
JP6896247B2 (ja) Ｇｌｐ−１分泌促進剤
EP3720467B1 (en) Methods for treatment of neuropathic pain
KR20180027924A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물